A novel, covalent broad-spectrum inhibitor targeting human coronavirus Mpro

Jing Sun, Deheng Sun, Qi Yang, Dong Wang, Jingjing Peng, Hu Guo, Xiaoyu Ding, Chen Zhao, Bin Yuan, Yan A. Ivanenkov, Jinwei Yuan, Bogdan Zagribelnyy, Yiyun He, Jingyi Su, Duo Li, Jielin Tang, Zhun Li, Rong Li, Taotao Li, Xiaoyu Hu, Xing Liang, Airu Zhu, Peilan Wei, Yaya Fan, Sang Liu, Jie Zheng, Xin Guan, Alexander Aliper, Minglei Yang, Dmitry S. Bezrukov, Zhanhong Xie, Victor A. Terentiev, Guilin Peng, Daniil Polykovskiy, А. В. Малышев, Maxim N. Malkov, Qingsong Zhu, Alán Aspuru‐Guzik, Xin Cai, Man Zhang, Jingxian Zhao, Jincun Zhao, Feng Ren, Xinwen Chen, Alex ZhavoronkovNature Communications 2025 · DOI

Abstract

Human coronaviruses (CoV) cause respiratory infections that range from mild to severe. CoVs are a large family of viruses with considerable genetic heterogeneity and a multitude of viral types, making preventing and treating these viruses difficult. Comprehensive treatments that inhibit CoV infections fulfill a pressing medical need and may be immensely valuable in managing emerging and endemic CoV infections. As the main protease ($M^{pro}$) is highly conserved across many CoVs, this protease has been identified as a route for broad CoV inhibition. We utilize the advanced generative chemistry platform Chemistry42 for de novo molecular design and obtained novel small-molecule, non-peptide-like inhibitors targeting the SARS-CoV-2 $M^{pro}$. ISM3312 is identified as an irreversible, covalent $M^{pro}$ inhibitor from extensive virtual screening and structure-based optimization efforts. ISM3312 exhibits low off-target risk and outstanding antiviral activity against multiple human coronaviruses, including SARS-CoV-2, MERS-CoV, 229E, OC43, NL63, and HKU1 independent of P-glycoprotein (P-gp) inhibition. Furthermore, ISM3312 shows significant inhibitory effects against Nirmatrelvir-resistant $M^{pro}$ mutants, suggesting ISM3312 may contribute to reduced viral escape in these settings. Incorporating ISM3312 and Nirmatrelvir into antiviral strategy could improve preparedness and reinforce defenses against future coronavirus threats.

Introduction: The Challenge of Coronavirus Evolution

While vaccines have been a cornerstone of the COVID-19 response, the rapid evolution of coronaviruses (CoVs) and the emergence of treatment-resistant strains present a moving target. Current oral antivirals like Nirmatrelvir (the active component of Paxlovid) face two major hurdles: metabolic dependency and viral escape. Nirmatrelvir is rapidly cleared by the body and must be co-administered with Ritonavir, a "booster" that inhibits the CYP3A enzyme. This leads to a high risk of drug-drug interactions, making it unsuitable for many patients on other medications. Furthermore, mutations in the $M^{pro}$ enzyme (the drug's target) are already appearing, which reduce the efficacy of existing inhibitors. This research presents ISM3312, a "broad-spectrum" inhibitor designed to target the highly conserved $M^{pro}$ across the entire coronavirus family while working independently of boosters.

Methods: AI-Driven Molecular Discovery

The discovery of ISM3312 utilized Chemistry42, an automated generative chemistry platform integrating over 40 AI models, including Generative Adversarial Networks and Variational Autoencoders. The discovery process followed a rigorous three-round structure-based drug design (SBDD) workflow.

The three-round structure-based drug design (SBDD) workflow using the Chemistry42 generative AI platform.

In Round 1, virtual screening of vendor libraries identified a primary hit based on a 4C-Ugi reaction scaffold. Round 2 focused on AI-driven hit expansion and optimization of a chloroacetamide lead. Finally, Round 3 refined the "warhead," swapping the standard chloroacetamide for an $\alpha$-chlorofluoroacetamide (CFA). This modification lowered covalent reactivity to reduce off-target risks while simultaneously improving metabolic stability in human and mouse plasma. The AI was guided by published X-ray structures of SARS-CoV-2 $M^{pro}$ (PDB: 6W63, 3V3M, and 6LU7), and its modules were trained on cysteine protease inhibitors from the ChEMBL database.

Key Insights and Results

Lead optimization revealed that the introduction of a methyl group at a specific quaternary carbon—the so-called "magic methyl"—significantly improved the molecule's binding conformation, boosting enzymatic potency to an $IC_{50}$ of 14 nM. Unlike many existing treatments, ISM3312 is not a significant substrate for the P-glycoprotein (P-gp) efflux pump, allowing it to reach therapeutic concentrations without the need for a booster drug like Ritonavir.

Chemical structure of the optimized lead compound, demonstrating the alpha-chlorofluoroacetamide (CFA) warhead and the potency-enhancing methyl group.

ISM3312 forms a permanent covalent bond with the C145 residue of the $M^{pro}$ active site. This irreversible nature provides a longer pharmacological half-life than reversible inhibitors. In cell assays, the compound maintained sub-micromolar $EC_{50}$ values across all tested variants, including MERS-CoV and common cold viruses (HCoV-229E, OC43, NL63, and HKU1). In vivo testing in mouse models infected with various SARS-CoV-2 strains (Ancestral, BA.2.3, and XBB.1) showed that oral administration of ISM3312 provided 100% protection and significantly reduced viral titers in the lungs and brain.

Conclusion and Clinical Outlook

ISM3312 represents a significant step forward in broad-spectrum antiviral development. By overcoming current resistance mechanisms (such as the E166V mutation) and eliminating the need for metabolic boosters, it offers a more flexible treatment option for diverse patient populations. While the CFA warhead reduces off-target risks, long-term safety profiles continue to be established. The compound has successfully completed a Phase I clinical trial in healthy volunteers, demonstrating its potential for rapid translation into clinical use to defend against current and future coronavirus threats.

Summary updated

Abstract

Human coronaviruses (CoV) cause respiratory infections that range from mild to severe. CoVs are a large family of viruses with considerable genetic heterogeneity and a multitude of viral types, making preventing and treating these viruses difficult. Comprehensive treatments that inhibit CoV infections fulfill a pressing medical need and may be immensely valuable in managing emerging and endemic CoV infections. As the main protease (M<sup>pro</sup>) is highly conserved across many CoVs, this protease has been identified as a route for broad CoV inhibition. We utilize the advanced generative chemistry platform Chemistry42 for de novo molecular design and obtained novel small-molecule, non-peptide-like inhibitors targeting the SARS-CoV-2 M<sup>pro</sup>. ISM3312 is identified as an irreversible, covalent M<sup>pro</sup> inhibitor from extensive virtual screening and structure-based optimization efforts. ISM3312 exhibits low off-target risk and outstanding antiviral activity against multiple human coronaviruses, including SARS-CoV-2, MERS-CoV, 229E, OC43, NL63, and HKU1 independent of P-glycoprotein (P-gp) inhibition. Furthermore, ISM3312 shows significant inhibitory effects against Nirmatrelvir-resistant M<sup>pro</sup> mutants, suggesting ISM3312 may contribute to reduced viral escape in these settings. Incorporating ISM3312 and Nirmatrelvir into antiviral strategy could improve preparedness and reinforce defenses against future coronavirus threats.
BibTeX
@inproceedings{sun2025novel,
  author = {Jing Sun and Deheng Sun and Qi Yang and Dong Wang and Jingjing Peng and Hu Guo and Xiaoyu Ding and Chen Zhao and Bin Yuan and Yan A. Ivanenkov and Jinwei Yuan and Bogdan Zagribelnyy and Yiyun He and Jingyi Su and Duo Li and Jielin Tang and Zhun Li and Rong Li and Taotao Li and Xiaoyu Hu and Xing Liang and Airu Zhu and Peilan Wei and Yaya Fan and Sang Liu and Jie Zheng and Xin Guan and Alexander Aliper and Minglei Yang and Dmitry S. Bezrukov and Zhanhong Xie and Victor A. Terentiev and Guilin Peng and Daniil Polykovskiy and А. В. Малышев and Maxim N. Malkov and Qingsong Zhu and Alán Aspuru‐Guzik and Xiao Ding and Xin Cai and Man Zhang and Jingxian Zhao and Jincun Zhao and Feng Ren and Xinwen Chen and Alex Zhavoronkov and Jincun Zhao},
  title = {{A novel, covalent broad-spectrum inhibitor targeting human coronavirus Mpro}},
  booktitle = {Nature Communications},
  year = {2025},
  doi = {10.1038/s41467-025-59870-4},
}
Figure